Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Nutrients ; 13(8)2021 Aug 11.
Artigo em Inglês | MEDLINE | ID: mdl-34444915

RESUMO

The feeding of colostrum and mother's transitional milk improves immune protection and neurodevelopmental outcomes. It also helps with gut maturation and decreases the risks of infection. The supply of nutrients from human milk (HM) is not adequate for preterm infants, even though preterm mother's milk contains higher concentrations of protein, sodium, zinc, and calcium than mature HM. The human milk fortifiers, particularly those with protein, calcium, and phosphate, should be used to supplement HM to meet the necessities of preterm infants. The management of fluid and electrolytes is a challenging aspect of neonatal care of preterm infants. Trace minerals such as iron, zinc, copper, iodine, manganese, molybdenum, selenium, chromium, and fluoride are considered essential for preterm infants. Vitamins such as A, D, E, and K play an important role in the prevention of morbidities, such as bronchopulmonary dysplasia, retinopathy of prematurity, and intraventricular hemorrhage. Therefore, supplementation of HM with required nutrients is recommended for all preterm infants.


Assuntos
Nutrição Enteral/métodos , Fenômenos Fisiológicos da Nutrição do Lactente/fisiologia , Doenças do Prematuro/prevenção & controle , Recém-Nascido Prematuro/crescimento & desenvolvimento , Recém-Nascido Prematuro/imunologia , Suplementos Nutricionais , Feminino , Alimentos Fortificados , Humanos , Lactente , Recém-Nascido , Masculino , Necessidades Nutricionais
2.
Can J Physiol Pharmacol ; 91(11): 935-40, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24117261

RESUMO

North American ginseng is known to have immunomodulatory and antipseudomonal properties in vitro. In this study we investigated the effects of aqueous ginseng extract, either alone or in a combination with the antibiotic tobramycin, in an animal model of chronic Pseudomonas aeruginosa lung infection. The lungs of male rats (n = 5) were infected with P. aeruginosa (2 × 10(8) cfu/mL) in agar-beads by intratracheal instillation. Starting on day 7 post-infection, animals were treated daily for 3 consecutive days with saline, tobramycin (300 µg/kg body mass, intratracheal), and (or) ginseng (100 mg/kg body mass, subcutaneous); animals were sacrificed 24 h after the third drug treatment. Lung bacteria counts, cytokine levels in sera, and lung histopathology were examined. The treatment of infected animals with tobramycin [6.6 × 10(4) colony forming units (cfu)], ginseng (5.3 × 10(4) cfu), or tobramycin plus ginseng (2.0 × 10(3) cfu) lessened the lung infection compared with the control group (saline treated) (6.0 × 10(6) cfu). The levels of pro-inflammatory cytokines (IL-2, IL-4, IL-6, IL-12p70, IFN-γ, GM-CSF, TNF-α) in infected animals were significantly increased with co-treatment of ginseng plus tobramycin. These data suggest that co-administration of aqueous ginseng extract and tobramycin stimulated the pro-inflammatory response and promoted the killing of P. aeruginosa.


Assuntos
Antibacterianos/farmacologia , Inflamação/fisiopatologia , Pneumopatias/tratamento farmacológico , Panax/química , Extratos Vegetais/farmacologia , Infecções por Pseudomonas/tratamento farmacológico , Pseudomonas aeruginosa/efeitos dos fármacos , Tobramicina/farmacologia , Ágar , Animais , Carga Bacteriana , Peso Corporal/efeitos dos fármacos , Quimiocinas/análise , Quimiocinas/metabolismo , Meios de Cultura , Citocinas/análise , Citocinas/metabolismo , Pulmão/patologia , Pneumopatias/microbiologia , Pneumopatias/patologia , Masculino , Tamanho do Órgão/efeitos dos fármacos , Infecções por Pseudomonas/microbiologia , Infecções por Pseudomonas/patologia , Ratos , Ratos Sprague-Dawley
3.
Can J Physiol Pharmacol ; 89(6): 419-27, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21815782

RESUMO

This study was carried out to examine the antimicrobial activity of the aqueous extract of Panax quinquefolius from North American ginseng (NAGE) root against Pseudomonas aeruginosa . The minimum inhibitory concentrations of reference and clinical isolates of Pseudomonas aeruginosa were measured by a standard agar-dilution method. At subinhibitory NAGE concentrations, the secretion of virulence factors, motility on agar, and adhesion to 96-well microplates were studied on the nonmucoid Pseudomonas aeruginosa O1 strain. At suprainhibitory concentrations, the activity of NAGE against mature biofilm complexes formed in the Calgary Biofilm Device and the Stovall flow cell were assessed. NAGE possessed an antibacterial activity against all the Pseudomonas aeruginosa strains at 1.25%-2.5% w/v. NAGE also significantly attenuated pyocyanin, pyoverdine, and lipase concentrations, stimulated twitching, and attenuated swarming and swimming motility. At 1.25% w/v, NAGE augmented adhesion, and at 5% w/v detached 1-day-old biofilms in microplates. The extract also eradicated 6-day-old mature biofilms (5% w/v), and fluorescence microscopy displayed a reduction of live cells and biofilm complexes compared with nontreated biofilms. These data suggest that the aqueous extract from North American ginseng possesses antimicrobial activities in vitro.


Assuntos
Antibacterianos/farmacologia , Biofilmes/efeitos dos fármacos , Panax , Fitoterapia , Extratos Vegetais/farmacologia , Pseudomonas aeruginosa/efeitos dos fármacos , Fatores de Virulência/biossíntese , Antibacterianos/química , Fibrose Cística/microbiologia , Humanos , Testes de Sensibilidade Microbiana , Oligopeptídeos/biossíntese , Extratos Vegetais/química , Raízes de Plantas , Infecções por Pseudomonas/microbiologia , Pseudomonas aeruginosa/isolamento & purificação , Pseudomonas aeruginosa/patogenicidade , Pseudomonas aeruginosa/fisiologia , Piocianina/biossíntese , Virulência/efeitos dos fármacos
4.
Biochem Pharmacol ; 64(9): 1407-13, 2002 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-12392822

RESUMO

The bactericidal effectiveness of liposomal polymyxin B against Pseudomonas aeruginosa was investigated in an animal model of pulmonary infection. Polymyxin B was incorporated into liposomes composed of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol (Chol) (2:1). Lung infection was induced in rats following intratracheal instillation of 10(7) colony-forming units (CFU) of P. aeruginosa (ATCC 27853) embedded in agar beads. Starting on day 3 post-infection, animals were treated daily, for 3 consecutive days, with saline, empty liposomes, free polymyxin B, or liposomal polymyxin B (2mg polymyxin B/kg body weight) by intratracheal instillation; animals were killed 24hr after the third drug instillation. Treatment of infected animals with liposomal polymyxin B significantly reduced the pulmonary bacterial counts (3.7+/-0.4log CFU/paired lungs) as compared with that of free polymyxin B (5.1+/-0.2log CFU/paired lungs). Treatment of infected animals with empty liposomes gave pulmonary bacterial counts similar to those obtained from the saline-treated group. Pulmonary infection with P. aeruginosa also resulted in lung injury as evidenced by increases in wet lung weight and decreases in angiotensin converting enzyme activity as well as increases in myeloperoxidase activity, an index of the inflammatory response. Treatment with free polymyxin B ameliorated the lung injuries induced by the microorganism, a protective effect that was more pronounced in the liposomal polymyxin B-treated group. The levels of polymyxin B in the lungs of the infected animals treated with the liposomal suspension were significantly higher (42.8+/-6.2 microg/paired lungs) compared with those treated with the free drug (8.2+/-0.4 microg/paired lungs). These data suggest that direct delivery of liposomal polymyxin B to the lung can be effective in the treatment of pulmonary infection with P. aeruginosa by enhancing retention of the antibiotic in the lung.


Assuntos
Antibacterianos/uso terapêutico , Sistemas de Liberação de Medicamentos , Pneumopatias/tratamento farmacológico , Polimixina B/uso terapêutico , Infecções por Pseudomonas/tratamento farmacológico , Animais , Antibacterianos/administração & dosagem , Antibacterianos/farmacocinética , Modelos Animais de Doenças , Portadores de Fármacos , Rim/metabolismo , Lipossomos , Pneumopatias/metabolismo , Pneumopatias/fisiopatologia , Testes de Sensibilidade Microbiana , Tamanho do Órgão/efeitos dos fármacos , Peptidil Dipeptidase A/metabolismo , Peroxidase/metabolismo , Fosfolipases A/metabolismo , Polimixina B/administração & dosagem , Polimixina B/farmacocinética , Pseudomonas aeruginosa/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA